STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Vaccines Review Article

Impact of Vaccine Awareness Campaigns on Pharmacovigilance Reporting and Public Safety Monitoring

  1. Suraj Sen Dept. of Pharmacy, Harishchandra Pharmacy College
  2. Anit Jha Dept. of Pharmacy, Harishchandra Pharmacy College
  3. Priyanshu Upadhyay Dept. of Pharmacy, Harishchandra Pharmacy College
  4. Rohit Dept. of Pharmacy, Harishchandra Pharmacy College
  5. Aman Kumar Dept. of Pharmacy, Harishchandra Pharmacy College
  6. Arvind Bhardwaj Dept. of Pharmacy, Harishchandra Pharmacy College

Abstract

Vaccination programs have significantly contributed to the reduction of infectious diseases worldwide; however, their success is closely tied to public confidence and robust safety monitoring systems. Pharmacovigilance plays a critical role in identifying, assessing, and preventing adverse events following immunization (AEFI). In recent years, vaccine awareness campaigns have emerged as a pivotal strategy to improve public knowledge, reduce vaccine hesitancy, and enhance reporting of adverse drug reactions (ADRs). This review explores the impact of vaccine awareness campaigns on pharmacovigilance reporting systems and overall public safety monitoring. It evaluates how educational interventions, media campaigns, and healthcare professional engagement influence reporting rates, data quality, and early detection of safety signals. Additionally, the article discusses global pharmacovigilance frameworks, reporting barriers, digital innovations, and the integration of awareness initiatives into surveillance systems. The findings suggest that awareness campaigns significantly improve spontaneous reporting rates, patient engagement, and transparency in vaccine safety monitoring. However, challenges, such as misinformation, underreporting, and variability in campaign effectiveness, persist. Strengthening communication strategies, integrating digital reporting tools, and fostering community trust are essential for optimizing pharmacovigilance outcomes.

Keywords

References (40)

  1. World Health Organization. Global vaccine safety blueprint 2.0 (GVSB2.0) 2021–2023.
  2. Pharmacovigilance WH. Ensuring the safe use of medicines. WHO policy perspective of medicine.
  3. Geneva: WHO; 2004.
  4. World Health Organization. The importance of pharmacovigilance.
  5. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse
  6. event reporting system (VAERS). Vaccine. 2015 Aug 26;33(36):4398–405.
  7. Castellana E, Budau PM, Chiappetta MR. Pharmacovigilance: Overview of Italian and European
  8. regulations, tools, and perspectives. Int J Risk Saf Med. 2025 Nov;36(4):147–55.
  9. Jadaun GP, Rastogi S, Kumar A, Chauhan J, Sharma SK, Kumar M, et al. Ensuring the quality of
  10. medicines in India: An update on the development, modernization, and harmonization of drug
  11. standards in the Indian Pharmacopoeia. Saudi Pharm J. 2023 Dec 1;31(12):101825.
  12. Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006 May;29(5):385–96.
  13. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug
  14. reactions: A systematic review. Drug Saf. 2009 Jan;32(1):19–31.
  15. Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around
  16. vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–
  17. 2012. Vaccine. 2014 Apr 17;32(19):2150–9.
  18. Betsch C, Böhm R, Chapman GB. Using behavioral insights to increase vaccination policy
  19. effectiveness. Policy Insights Behav Brain Sci. 2015 Oct;2(1):61–73.
  20. World Health Organization. COVID-19 vaccines: Safety surveillance manual. Geneva: World
  21. Health Organization; 2020 Dec 22.
  22. Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, et al. Importance of background
  23. rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1
  24. influenza vaccines. Lancet. 2009 Dec 19;374(9707):2115–22.
  25. Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug–drug interactions in
  26. Regione Emilia‐Romagna, Italy. J Clin Pharm Ther. 2008 Apr;33(2):141–51.
  27. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet.
  28. 2000 Oct 7;356(9237):1255–9.
  29. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health
  30. programmes: Complementing spontaneous reporting systems. Drug Saf. 2013 Feb;36(2):75–81.
  31. Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, et al. Digital drug safety
  32. surveillance: Monitoring pharmaceutical products in twitter. Drug Saf. 2014 May;37(5):343–50.
  33. Salathé M, Khandelwal S. Assessing vaccination sentiments with online social media: Implications
  34. for infectious disease dynamics and control. PLoS Comput Biol. 2011 Oct 13;7(10):e1002199.
  35. Wilson K, Atkinson K, Deeks S. Opportunities for utilizing new technologies to increase vaccine
  36. confidence. Expert Rev Vaccines. 2014 Aug 1;13(8):969–77.
  37. Orenstein WA, Ahmed R. Simply put: Vaccination saves lives. Proc Natl Acad Sci U S A. 2017
  38. Apr 18;114(16):4031–3.
  39. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug
  40. Saf. 1999 Feb;20(2):109–17.